🌍 Shaping the Future of Indian Pharma At the OPPI India Annual Summit 2024, industry leaders gathered to discuss transformative strategies for establishing India as a global pharmaceutical powerhouse. 💊 With insights on innovation, sustainability, and collaboration, the event underscored India's potential to lead in delivering affordable, high-quality healthcare solutions to the world. 📖 Dive deeper into the key takeaways and industry vision here: #PharmaLeadership #HealthcareInnovation #IndiaPharma #OPPI2024
FE Healthcare’s Post
More Relevant Posts
-
Centered around the theme Viksit Bharat @2047 — India's Path from the 'Pharmacy of the World' to the 'Pharma Powerhouse to the World', the summit set forth the vision for India's healthcare evolution. Organisation of Pharmaceutical Producers of India #healthcare #PharmaIndustrialIndia
OPPI Annual Summit Presents Roadmap on Becoming Pharma Powerhouse Globally - Global Pharma
pharmaindustrial-india.com
-
Auto-Injectors Market Size, Share & Trends Analysis Report by Type (Disposable Auto-injectors, and Reusable Auto-injectors), by Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), and by End-User (Home Care Settings, Hospitals & Clinics, and Others) Forecast Period (2024-2031) Get Sample of Report at:https://bit.ly/3S3MI6l Auto-Injectors market is anticipated to grow at a CAGR of 15.1% during the forecast period (2024-2031). The auto-injector market is driven by factors such as rising allergies, chronic diseases, technological advancements, and patient preference for self-administration. The regulatory support and cost-effectiveness of these auto-injectors further support its adoption. Regulatory support facilitates market entry while emerging markets' healthcare infrastructure development increases access to auto-injectors. #AutoInjectors #MedicalDevices #HealthcareInnovation #InjectionTechnology #PharmaTech #DrugDelivery #AutoInjectorMarket #PatientCare #SelfInjection #Pharmaceuticals #HealthTech #MedicationManagement #NextGenHealthcare #MedicalInnovation #Biotech Key Players:ApiJect Systems, AstraZeneca, BD, Eli Lilly and Company, Midas Pharma, Novartis, Otsuka Holdings Co., Ltd., Owen Mumford, Recipharm, Sanofi, SHL Medical, Teva Pharmaceuticals, Viatris, West Pharmaceutical Services, Ypsomed AG, among others.
-
-
Join us this week at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com rizza@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence
RWE, Market Access, Pricing & Reimbursement 2024 Europe
https://www.marketaccesseurope.com
-
What’s the role of Pharma industry in VBHC implementation? During the executive education program at American University in Bulgaria there will be case studies from many countries and Bulgaria, panel discussion and real-world cases presented by the VBHC champions of the region during the VBHC conference on October 27th. How VBHC projects supported by industry optimized the patient journey, improved capacity, introduced outcome measurement and designed value-based payments - all of this shared as experience working with Future Values and HTA Ltd. Approximately 30% of the participants in the program are executives from the industry from CEE and they will contribute to this important discussion. #VBHC #pharma #outcomemeasurement #costmeasurement #healthcareinnovation #TDABC
How the Pharma Industry Can Support Value-Based Care The pharmaceutical industry plays a critical role in the transition to Value-Based Healthcare (VBHC). By aligning innovations in treatment and drug development with patient outcomes, the pharma sector can be a key driver of healthcare transformation. At the Leadership and Value Creation in Healthcare program, we will explore how the pharmaceutical industry can support and enhance value-based care initiatives. This discussion will cover: - Innovative Payment Models: How outcomes-based contracts and value-driven pricing strategies can ensure patients receive the treatments they need while maintaining cost-effectiveness. - Collaborative Efforts with Healthcare Providers: The importance of partnerships between pharma companies, payers and healthcare providers to ensure the right treatments reach the right patients. - Pharma’s Role in Outcome Measurement: The impact of real-world evidence and patient-reported outcomes in creating value and improving healthcare delivery. Join us for an exclusive Panel Discussion on Day 2, focused on The Role of Industry in Supporting Value-Based Care Implementation, featuring insights from industry leaders, this session will examine how pharmaceutical companies and the wider healthcare industry can work together to support VBHC implementation and foster innovation. This session is essential for those in the pharmaceutical industry and policy makers looking to stay ahead in a rapidly evolving healthcare environment. Learn how your organization can be part of the value-based healthcare movement. 📅 Dates: October 24-27, 2024 🔗 Apply by October 10th: https://lnkd.in/dQmuQKV3 ⚠️ Limited Seats Available: Time is running out—apply now to secure your spot! #HealthcareLeadership #PharmaceuticalIndustry #ValueBasedCare #HealthcareInnovation #OutcomeMeasurement #HealthcarePolicy #AUBG #HealthcareTransformation #FutureValues #HarvardBusinessSchool American University in Bulgaria, Harvard Business School, HTA Ltd. . Dr. Slaveyko Djambazov, Yoanna Vutova, Adriana Dacheva, PhD, Ruslana Toncheva, Nick Guldemond, David N. Bernstein, Sandra Romenska
-
-
Project Lead: Orphan Drugs & Rare Diseases -Precision for Medicine, Patient Centricity & Engagement at Paradigm Global Events
Register Now ! Join us at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com danna@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence
RWE, Market Access, Pricing & Reimbursement 2024 Europe
https://www.marketaccesseurope.com
-
Project Lead: Orphan Drugs & Rare Diseases -Precision for Medicine, Patient Centricity & Engagement at Paradigm Global Events
Register Now ! Join us at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com danna@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence
RWE, Market Access, Pricing & Reimbursement 2024 Europe
https://www.marketaccesseurope.com
-
Register Now ! Join us at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com rizza@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #datamanagemnet #realworldevidence #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #even
RWE, Market Access, Pricing & Reimbursement 2024 Europe
https://www.marketaccesseurope.com
-
Biologist|| Passionate Content Creator & Story Teller || Techno Commercial Professional of CarciReagent IVD self testing kit Oncology Biosimilars/Clinical trials phase studies
#Accesstoessentialmedicines Pharma industry faces call to expand patient access in low- and middle-income countries A new report from the Access to Medicine Foundation provides an analysis of how some of the largest pharmaceutical companies are working to reach patients worldwide, particularly in low- and middle-income countries (LMICs), in pursuit of health equity. The report evaluates their current approaches for measuring and reporting patient reach, emphasizing the need for more actionable strategies to improve access to essential healthcare products. The report was conducted ahead of the 2024 Access to Medicine Index and examined patient reach commitments and measurement approaches of 20 companies that will be ranked in the Index, set for release in November. The report reveals that these goals often lack the precision needed to achieve meaningful impact. Despite comprising 80% of the global population, people in LMICs face significant barriers in accessing essential healthcare products. Only six companies—Astellas, AstraZeneca, MSD, Novartis, Pfizer, Bayer and J& J reported patient reach methods that cover all countries in which they operate. The report points out that significant room for improvement remains, particularly for major insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi.
-
-
Project Lead: Orphan Drugs & Rare Diseases -Precision for Medicine, Patient Centricity & Engagement at Paradigm Global Events
Register Now ! Join us at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com danna@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence
RWE, Market Access, Pricing & Reimbursement 2024 Europe
https://www.marketaccesseurope.com
-
Project Lead: Orphan Drugs & Rare Diseases -Precision for Medicine, Patient Centricity & Engagement at Paradigm Global Events
Register Now ! Join us at the 10th RWE, Market Access, Pricing & Reimbursement Global Congress 2024 Europe, taking place in London, UK on the 23rd - 24th May 2024. Event Website: www.marketaccesseurope.com For more information or to register early. info@paradigmglobalevents.com danna@paradigmglobalevents.com #MarketAccess #Reimbursemnet #patientoutcomes #drugpricing #healtheconomics #outcomesresearch #payerrelations #evidence #regulatoryaffairs #valuestrategy #patientaccess #realworlddata #clinicaltrials #clinicalresearch #clinicaldevelopment #dataanalytics #pharmaceuticals #biotechnology #rwe #marketaccess #pricingandreimbursement #healtheconomics #outcomesresearch #datamanagement #patientoutcomes #earlydevelopment #pricingstrategy #pricing #reimbursement #datamanagement #realworldevidence
RWE, Market Access, Pricing & Reimbursement 2024 Europe
https://www.marketaccesseurope.com
More from this author
-
New WHO report reveals decline in per capita government health spending across all income groups
-
Snakebites declared a ‘Notifiable Disease’ in India; Health experts anticipate improved surveillance and compliance
-
FE Mental Health Series | Rising burnout and workplace-related suicides put employees’ well-being in focus